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A B S T R A C T
Background
It has been proposed that antioxidants may prevent cellular damage in the retina by reacting with free radicals produced in the process
of light absorption.
Objectives
The objective of this review is to assess the effects of antioxidant vitamin and/or mineral supplementation on the progression of age-
related macular degeneration.
Search strategy
The Cochrane Controlled Trials Register - CENTRAL/CCTR, which contains the Cochrane Eyes and Vision Group specialised register
(Cochrane Library Issue 3 2001), MEDLINE (1966 to August 2001), EMBASE (1980 to September 2001), the Science Citation
Index, and the reference lists of relevant articles were searched. Investigators of included studies were contacted for further information.
Selection criteria
Randomised trials comparing an antioxidant vitamin and/or mineral supplement (alone or in combination) to control in people with
age-related macular degeneration are included in this review.
Data collection and analysis
The reviewer extracted data and assessed trial quality. Due to the variable methods of collecting and presenting outcome data, no
statistical summary measure was calculated.
Main results
Seven trials, which randomised 4119 people with signs of age-relatedmacular degeneration, are included in this review.One unpublished
trial of zinc supplementation (170 participants) is awaiting assessment. The majority of people (88%) were randomised in one trial that
found a modest beneficial effect of antioxidant and zinc supplementation on progression to advanced age-related macular degeneration
(odds ratio 0.72, 99% confidence interval 0.52 to 0.98). People supplemented with antioxidants and zinc were less likely to lose 15
or more letters of visual acuity (equivalent to a doubling of the visual angle) (odds ratio 0.79, 99% confidence interval 0.60 to 1.04).
This effect was seen more strongly in people with moderate to severe disease. There were few events in people with early signs of the
disease. The trial evaluated many safety outcomes, of which hospitalisation for genitourinary problems was more common in people
taking zinc and yellowing of skin was more common in people taking antioxidant micronutrients. The other six trials in this review
were small and the results were inconsistent.
Authors’ conclusions
The evidence as to the effectiveness of antioxidant vitamin and mineral supplementation in halting the progression of age-related
macular degeneration is dominated by one large trial that showed modest benefit in people with moderate to severe signs of the disease.
There is no evidence at present that people with early signs of the disease should take supplementation, however, current studies are
underpowered to answer that question. Long term harm from supplementation cannot be ruled out, particularly in smokers. The
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generalisability of these findings to other populations with different nutritional statuses is not known. Further large well-conducted
randomised controlled trials in other populations are required.
P L A I N L A N G U A G E S U M M A R Y
Antioxidant vitamin or mineral supplementation in people with moderate to severe age-related macular degeneration may have modest
benefits in delaying the progression of the disease
The retina (the light sensitive layer at the back of the eye) can deteriorate with age. Some people get lesions called ’age-related macular
degeneration’ that can lead to loss of central vision. It has been suggested that progression of the disease may be slowed down in people
who eat a diet rich in antioxidant vitamins (carotenoids, vitamins C and E) or minerals (selenium and zinc). The review of trials found
that supplementation with antioxidants and zinc may be of modest benefit in people with moderate to severe disease. Long term harm
from these supplements cannot be ruled out. More trials in other populations are required.
B A C K G R O U N D
Age-related macular degeneration is a disease affecting the central
area of the retina (macula). In the early stages of the disease lipid
material accumulates in deposits underneath the retinal pigment
epithelium. These deposits are known as drusen, and can be seen as
pale yellow spots on the retina. The pigment of the retinal pigment
epithelium may become disturbed with areas of hyperpigmenta-
tion and hypopigmentation. In the later stages of the disease, the
retinal pigment epitheliummay atrophy completely. This loss can
occur in small focal areas or can be widespread (geographic). In
some cases, new blood vessels grow under the retinal pigment ep-
ithelium and occasionally into the subretinal space (exudative or
neovascular age-related macular degeneration). Haemorrhage can
occur which often results in increased scarring of the retina.
The early stages of the disease are in general asymptomatic. In
the later stages there may be considerable distortion of vision and
complete loss of visual function, particularly in the central area of
vision. Population-based studies suggest that in people 75 years
and older, approximately 30 per cent have early signs of the dis-
ease and seven per cent have late stage disease (Klein 1992). It
is the most common cause of blindness and visual impairment
in industrialised countries. In the UK for example, over 30,000
people are registered as blind or partially sighted annually, half of
whom have lost their vision due to macular degeneration (Evans
1996). Currently there is no treatment that can restore vision in
age-related macular degeneration.
Photoreceptors in the retina are subject to oxidative stress through-
out life due to combined exposures to light and oxygen. It has
been proposed that antioxidants may prevent cellular damage in
the retina by limiting the damaging effects of free radicals pro-
duced in the process of light absorption (for a review see Christen
1996). Antioxidant vitamin and mineral supplements are increas-
ingly being marketed for use in age-related eye disease, including
age-related macular degeneration.
O B J E C T I V E S
The objective of this review is to assess the effects of antioxidant
vitamin and/or mineral supplementation on the progression of
age-related macular degeneration.
C R I T E R I A F O R C O N S I D E R I N G
S T U D I E S F O R T H I S R E V I E W
Types of studies
This review includes only randomised controlled trials.
Types of participants
Participants in the trials were people with age-related macular de-
generation in one or both eyes.
Types of intervention
Trials in which antioxidant vitamin and/or mineral supplemen-
tation was compared to placebo or no intervention are included.
Antioxidants were defined as any vitamin or mineral which is
known to have antioxidant properties in vivo or which is known
to be an important component of an antioxidant enzyme present
in the retina. The following were considered: vitamin C, vitamin
E, carotenoids, selenium and zinc.
Types of outcome measures
The following outcomes were used:
(1) number of participants with disease progression,
(2) number of participants with new visual loss due to age-related
macular degeneration,
(3) quality of life measures,
(4) any adverse outcomes as reported in trials.
The following definitions were used:
2Antioxidant vitamin and mineral supplements for age-related macular degeneration (Review)
Copyright © 2006 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
• Age-related macular degeneration: this was taken as defined by
trial investigators. It is commonly defined as: in the macular
area 3000 microns diameter from fovea: drusen with or without
pigmentary abnormalities or geographic atrophy or character-
istic choroidal neovascularisation with no other cause.
• Progression of disease: development of drusen, geographic at-
rophy or growth or progression of new vessels in the retina.
• Visual loss: any well-defined outcome based on visual acuity
was used depending on the way in which authors presented trial
data. Other validated measures of visual loss, such as contrast
sensitivity, were used where available.
• Quality of life: any validated measurement scale.
S E A R C H M E T H O D S F O R
I D E N T I F I C A T I O N O F S T U D I E S
See: methods used in reviews.
Trials were identified from the Cochrane Controlled Trials
Register - CENTRAL/CCTR (which contains the Cochrane
Eyes and Vision Group specialised register) on the Cochrane
Library, MEDLINE and EMBASE.
The following strategy was used to search CENTRAL Issue 3
2001:
#1 MACULAR-DEGENERATION:ME
#2 RETINAL-DEGENERATION:ME
#3 NEOVASCULARIZATION-PATHOLOGIC*:ME
#4 ((((((MACULA or MACULAR) or RETINA) or RETINAL)
or CHOROID) or CHOROIDAL) near (DEGENERATION or
NEOVASCULARIZATION) or NEOVASCULARISATION)
#5 MACULOPATHY
#6 ((((#1 or #2) or #3) or #4) or #5)
#7 ((((AGE next RELATED) or AGE-RELATED) or AGEING)
or AGING)
#8 (#6 AND #7)
The following strategy was used to search MEDLINE on
SilverPlatter to August 2001:
#1 “MACULAR-DEGENERATION”/ all subheadings
#2 “RETINAL-DEGENERATION”/ all subheadings
#3 “NEOVASCULARIZATION,-PATHOLOGIC”/ all
subheadings
#4 “RETINAL-NEOVASCULARIZATION”/ all subheadings
#5 “CHOROIDAL-NEOVASCULARIZATION”/ all
subheadings
#6 #1 or #2 or #3 or #4 or #5
#7 (MACUL* or RETINA* or CHOROID*) near (DEGENER*
or NEOVASC*) in TI,AB
#8 MACULOPATHY in TI,AB
#9 (AGE or AG?ING or AGE?RELATED or SENIL*) in TI,AB
#10 (#6 or #7 or #8) and #9
To identify randomised controlled trials, this search was
combined with the Cochrane Highly Sensitive Search Strategy
phases one and two as contained in the Cochrane Reviewers’
Handbook (Clarke 2000).
The following strategy was used to search EMBASE on
SilverPlatter to September 2001:
#1 explode “RETINA-MACULA-DEGENERATION”/ all
subheadings
#2 “RETINA-DEGENERATION”/ all subheadings
#3 “NEOVASCULARIZATION-(PATHOLOGY)”/ all
subheadings
#4 “SUBRETINAL-NEOVASCULARIZATION”/ all
subheadings
#5 ((MACUL* or RETINA* or CHOROID*) near
(DEGENER* or NEOVASC*)) in TI,AB
#6 MACULOPATHY in TI,AB
#7 (AGE?RELATED or AGE RELATED OR AG?ING OR
SENIL*) IN TI,AB
#8 (#1 or #2 or #3 or #4 or #5 or #6) and #7
To identify randomised controlled trials, this search was
combined with the following search:
#1 “RANDOMIZED-CONTROLLED-TRIAL”/ all
subheadings
#2 “RANDOMIZATION”/ all subheadings
#3 “CONTROLLED-STUDY”/ all subheadings
#4 “MULTICENTER-STUDY”/ all subheadings
#5 “PHASE-3-CLINICAL-TRIAL”/ all subheadings
#6 “PHASE-4-CLINICAL-TRIAL”/ all subheadings
#7 “DOUBLE-BLIND-PROCEDURE”/ all subheadings
#8 “SINGLE-BLIND-PROCEDURE”/ all subheadings
#9 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8
#10 RANDOM* or CROSS?OVER* or FACTORIAL* or
PLACEBO* or VOLUNTEER* in TI,AB
#11 (SINGL* or DOUBL* or TREBL* or TRIPL*) near
(BLIND* or MASK*) in TI,AB
#12 #9 or #10 or #11
#13 HUMAN in DER
#14 (ANIMAL or NONHUMAN) in DER
#15 #13 and #14
#16 #14 not #15
#17 #12 not #16
No additional search terms for antioxidant vitamin and mineral
supplements were used. All possible age-related macular
degeneration trials were examined for trials of vitamin and
mineral supplements.
The reference lists of identified trial reports were searched to find
additional trials. The Science Citation Index was used to find
studies that cite the identified trials. Investigators of included
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studies were contacted to identify additional published and
unpublished studies.
Searches were first performed in August 1997 and repeated in
October 1998, December 1999, September 2000 and November
2001.
M E T H O D S O F T H E R E V I E W
Selection of trials
The reviewer assessed the titles and abstracts of all reports of trials
identified by the electronic searching. The full text hard copies of
possible trials of antioxidant vitamin and/or mineral supplements
were obtained. Relevant studies were selected according to the
definitions in the ’Criteria for considering studies for this review’.
Assessment of methodological quality
Trial quality was assessed according to methods set out in section
6 of the Cochrane Reviewer’s Handbook. Five parameters were
considered: allocation concealment, method of allocation to
treatment, documentation of exclusions, masking of outcome
assessment and completeness of follow-up.
Each parameter of trial quality was graded: A - low risk of bias;
B - moderate risk of bias; and C - high risk of bias. The assessor
was not masked to the report authors and trial results. The a
priori criterion for exclusion was that trials scoring C on allocation
concealment (that is, where allocation was not concealed properly)
were excluded.
Data collection
The reviewer extracted data using a standardised form developed
by the Cochrane Eyes and Vision Group. These data were sent for
verification to the trial investigators of all studies included in the
review.
Data synthesis
Due to the small number of trials identified, and variable methods
of collecting and presenting outcome data, no summary measure
was calculated.
D E S C R I P T I O N O F S T U D I E S
Finding the trials
The original electronic searches identified 577 reports of possi-
ble age-related macular degeneration (AMD) trials of which five
reports (four trials) were of antioxidant interventions (Newsome
1988; Kaiser 1995; AMDSG; Stur 1996). These four trials met
the inclusion criteria for this review. Contact with a trial author
identified an additional trial of zinc supplementation that has been
published in abstract form only (Holz 1993).
In October 2001, the result of the Age-Related Eye Disease Study
(AREDS) was published. The reference list of this study report
identified that the Vitamin E, Cataract and Age-relatedmaculopa-
thy study (VECAT) had been published in abstract form.
Searching the reference lists of trial reports located one further
possible relevant trial (Vannas 1958). This study was not included
in the review because there was no evidence from the report that
the comparison groups (heparin, vitaminA&E,Hydergin therapy
and placebo) were randomly allocated or that the allocation was
concealed in any way. As the trial was conducted in 1958, no
further attempt was made to clarify this.
A trial of zinc supplementation (30 milligrams (mg) daily) of peo-
ple with neovascular AMD in one eye and drusen in the other (n =
170) has been conducted and is as yet unpublished (France 1998).
This trial is listed as ’Awaiting assessment’ in this review.
See the Table of Included Studies for detailed information about
the seven trials included in this review.
Types of participants
The average age of people participating in the trials was 70 years.
Slightly more women than men were recruited with the exception
of the AMDSG where predominantly men were enrolled. In the
AREDS study it was noted that people taking part in the trial were
relativelywell-nourished compared to the general population.This
is commonly found in clinical trials.
People taking part in the trials were identified by referral from lo-
cal ophthalmologists (Newsome 1988; Kaiser 1995), from people
attending Department of Veterans Medical Centers (AMDSG),
from retinal specialty clinics and general population volunteers
(AREDS), an eye outpatient clinic (Stur 1996) and general pop-
ulation (VECAT).
The trials enrolled groups of people with AMD at different stages
of the disease: the AMDSG considered people with early macular
degeneration only; Newsome 1988 examined people with both
early and late stage disease; Stur 1996 enrolled only people with
late stage disease in one eye; Kaiser 1995 recruited only people with
geographic AMD. In the AREDS study participants had a range of
disease from mild or borderline features to advanced AMD which
was defined as geographic atrophy involving the centre of themac-
ula or features of choroidal neovascularization. The majority of
the participants in the VECAT study had no or mild age-related
maculopathy.
Types of intervention
Three trials compared zinc sulfate 200 milligrams daily versus
placebo (Newsome 1988; Holz 1993; Stur 1996). Two trials
compared a broad-spectrum antioxidant complex versus placebo
(AMDSG -Ocuguard; Kaiser 1995 -Visaline). TheVECAT study
compared vitamin E (500 international units (IU) daily) with
placebo. In AREDS a 2x2 factorial design was used. Participants
were randomised into four groups: placebo, zinc alone (80 mg
daily), antioxidants (vitamin C 500 mg, vitamin E 400 IU and
beta-carotene 15 mg) alone and zinc plus antioxidants. 67% of
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participants inAREDS took additionalmultivitamin supplements
to recommended daily allowance levels (Centrum).
The duration of supplementation in these trials ranged from six
months to seven years.
Types of outcome measures
All the trials used different outcome measures for visual function
and progression of disease. The AMDSG measured vision using
Snellen acuity and converted the score into logMAR units. New-
some 1988 and AREDS used the visual acuity chart developed as
part of the Early Treatment of Diabetic Retinopathy Study (ET-
DRS 1980). Stur 1996 and VECAT used Bailey-Lovie Charts
#4 and #5 (National Vision Research Institute, Australia). Some
studies have presented vision as a continuous outcome (AMDSG;
Kaiser 1995; Stur 1996), others have used a cut-off of loss of 10
(Newsome 1988) or 15 letters of acuity (AREDS). A loss of 15
letters of acuity is equivalent to a loss of three lines of vision read
on the chart and is the same as experiencing a doubling of the
visual angle.
In most studies disease progression was assessed by grading stereo-
scopic colour photographs of the retina. Stur 1996 used the Wis-
consin Age-Related Maculopathy Grading System (Klein 1991);
AMDSG used the grading system developed as part of the Chesa-
peake Bay Waterman Study (Bressler 1989); VECAT used the In-
ternational Grading System (ARM Study Group 1995); AREDS
adapted the Wisonsin system. The Wisconsin, AREDS and In-
ternational Systems are closely related; the latter was published
after the two former were in use. All these grading systems involve
classification into categories according to the number and type
of drusen, pigmentary abnormalities and presence of geographic
atrophy or neovascularisation. In AMDSG and Stur 1996 these
categories were accorded a score which was analysed as a continu-
ous measure. Newsome 1988 recorded the number of cases of in-
creased drusen, pigment and atrophy. Kaiser 1995 did not include
any measures of progression of AMD.
M E T H O D O L O G I C A L Q U A L I T Y
All of the five trials that were published before 2001 were small -
the number of participants for which data were analysed ranged
from 20 to 151. In only one trial (Stur 1996) was an a priori
sample size estimate reported but the trial was terminated early
when follow-up of the first 40 patients showed no detectable trend.
The more recent trials, AREDS and VECAT, were larger at 3640
and 1204 participants respectively and were based on prior sam-
ple size calculations. In the case of VECAT, however, sample size
was based on estimated prevalence and incidence of cataract rather
than age-related maculopathy. In addition, most of the 1204 par-
ticipants did not have signs of age-related macular degeneration
at the beginning of the study and are therefore included in the
related Cochrane review on prevention of AMD (Evans 2001).
Inmost trials randomisation appeared to have been executed prop-
erly, that is, an unpredictable sequence of treatment allocation
was concealed adequately from people recruiting participants into
the trial. As Holz 1993 has only been published in abstract form
to date the details of randomisation were not clear. In one trial
(AMDSG) more people in the placebo group withdrew (six) com-
pared to the treatment group (one). The description of the tablets
cannot exclude the possibility that there were detectable differ-
ences between treatment and placebo that may mean that some
participants in the study were unmasked. In AREDS four people
were documented as being unmasked to study group.More people
in the antioxidant group (8.3%) reported changes in skin colour
(yellowing) than in the placebo group (6.0%) P < 0.01 and more
people in the zinc arms reported difficulty swallowing the study
tablets (17.8% versus 15.3%, P = 0.04). However, there was lit-
tle evidence of unmasking - at the end of the study, participants
were asked to guess their treatment assignment. The percentages
of participants who guessed correctly, by treatment assignment
were: placebo 17%, antioxidants alone 16%; zinc alone 18%; and
antioxidants plus zinc 16%.
In one trial (Stur 1996) analysis of themain outcomemeasures (vi-
sual function and progression of disease) was not done on a strictly
intention-to-treat basis as anyone experiencing the endpoint of
late stage age-related macular degeneration (neovascularisation)
was withdrawn from the study. Contact with the trial investigator
revealed that all of these participants ended up with visual acuity
of 20/200 or less and that these participants were excluded because
the investigators wished to detect functional changes caused by
degeneration of the retinal pigment epithelium and the sensory
retina and not vision losses caused by choroidal neovascularisation.
R E S U L T S
The results of the studies could not be summarised meaningfully
because measures of vision and disease progression were presented
in different ways. The largest trial (AREDS) only presented odds
ratios derived from repeated measures logistic regression so these
could not be included in the graphical displays. The following
description highlights the main results from each study.
The AMDSG found an effect on visual acuity in the left eye only
(P = 0.03). The average visual acuity (logMAR score) of the left
eye of people in the placebo group was 0.24 (standard error 0.03)
at baseline and 0.40 (standard error 0.10) 18 months later; in
the antioxidant treatment group vision in the left eye remained
stable at 0.19 (standard error 0.03). There was no evidence of any
beneficial effect of antioxidant supplementation on progression of
the disease.However,more people in the control group (9/24) than
the intervention group (5/35) reported their vision had declined
at 18 months.
Kaiser 1995 found no difference between treatment and control in
objective measures of visual functioning although more people in
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the control group (3/10) than the treatment group (0/8) reported
deterioration in visual function.
Newsome 1988 found a clear effect on both vision and progression
of disease. People in the zinc treated group were less likely to lose
10 or more letters on the ETDRS chart than controls (odds ratio
0.33, 95% confidence interval 0.15 to 0.69) (equivalent to a loss
of two lines on the chart); there was evidence of slower progression
of disease in the treatment group. Stur 1996 showed no evidence
of any beneficial effect of zinc supplementation on visual function
or progression of age-relatedmacular degeneration, similarly,Holz
1993 showed no difference in the incidence of new exudative or
dry lesions (four versus two per group).
None of these trials contained information on quality of life and
they were too small to look for serious adverse effects. The main
reported adverse effect leading to withdrawal from the studies
was gastrointestinal symptoms. Of 286 people randomised into
trials of zinc sulfate supplementation compared to placebo, 5/146
zinc treated people withdrew due to gastrointestinal symptoms
compared to 2/140 controls. No-one developed copper deficiency
anaemia. In the AMDSG trial, one person developed an ’allergic
reaction’ although it was not clear whether or not this was related
to the treatment.
The results of VECAT have only been published in abstract form
at present. Although 1204 people were randomised initially, only
102 of those followed up to four years had early age-related mac-
ulopathy (ARM) at baseline. Of these 44 experienced worsening
of ARM over the study period but there was no evidence of any
benefit from vitamin E supplementation. There was also little evi-
dence of a reduction in the incidence of ARM in people previously
without the disease but these data are considered in the Cochrane
review on prevention of age-related macular degeneration (Evans
2001).
AREDS reported data for three categories of participant: (i)mild or
borderline AMD features (n = 1063); (ii) AMD but not advanced
AMD (n = 1621) and (iii) advanced AMDor reduced visual acuity
due to AMD in one eye (n=956). Advanced AMD was defined
as signs of geographic atrophy involving the centre of the macula
or signs of choroidal neovascularisation (defined as the presence
beneath the retinal pigment epithelium of sensory retina of fluid,
blood or fibrovascular or fibrous tissue).
The study followed up 90% of the cohort by the end of five years;
the mean follow-up time was 6.3 years. On the basis of having
missed last two consecutive study visits, 2.4% were defined as lost
to follow-up. In the borderline AMD group, 1.3% progressed to
advanced AMD by five years (15 AMD events); in the advanced
AMD category, 43% progressed to advanced AMD (in the other
eye) by five years and 18% progressed in the intermediate group.
At five year follow-up, 71% of participants were taking 75% or
more of their tablets.
The investigators found that individuals with outcomes such as
signs of advanced AMD and visual acuity loss of 15 or more letters
could recover later on. Approximately 8% of the identified cases
of advanced AMD, based on central grading of colour stereo pho-
tographs, apparently recovered as the AMD lesions were not seen
on subsequent yearly photographs. The report did not distinguish
between grading errors and verified disappearance of lesion. For
this reason they used repeated measures logistic regression which
counts each event but also allows for the fact that the event could
’recover’. A summary of their results is shown in Table 02 and
Table 03.
AREDS considered a number of safety outcomes. They conducted
over 100 comparisons of zinc versus no zinc and antioxidants ver-
sus no antioxidants. Participants in the antioxidant arms more
frequently reported yellow skin (8.3% versus 6.0%, P = 0.008).
Participants in the zinc arms reported more anaemia (13.2% ver-
sus 10.2%, P = 0.004) however serum haematocrit levels were the
same. They found that none of the individual treatments, when
compared with placebo, statistically significantly reduced or in-
creased the risk of mortality although the estimate is in the di-
rection of harm for participants who had never smoked. The trial
was not designed or powered to investigate effects on mortality
and therefore interpretation of this sub-group analysis should be
measured.
D I S C U S S I O N
Prior to 2001 there was little evidence as to the benefits and harms
of antioxidant supplementation in age-related macular degener-
ation. Previous versions of this review concluded that ’currently
available trials do not answer the question as to whether people
with age-related macular degeneration should take antioxidant vi-
tamin and mineral supplements in order to halt the progression
of the disease’ and that two large trials were ongoing in USA and
Australia. These trials have now been published (one in abstract
form) and are included in this review.
Table 01 shows the sample size and number of events in the trials
included in this review. There have been 4119 people with signs
of age-related macular degeneration randomised into trials of an-
tioxidant vitamin and mineral supplementation producing in the
region of 814 events. The majority of people (88%) have been
randomised in the AREDS trial which has produced the majority
of the events (88%). There is one additional trial of zinc supple-
mentation (30 milligrams) in 170 participants that has not yet
been published and is awaiting assessment in this review.
AREDS found a modest beneficial effect of antioxidant and zinc
supplementation on progression to advanced AMD. This effect
was seen most strongly in people with moderate or advanced signs
of the disease. They also found that people with moderate or ad-
vanced signs of the disease supplemented with antioxidants and
zinc were less likely to develop reduced vision. There were only 15
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’events’ in people withmild or borderline signs of the disease at five
years follow-up and this study was underpowered to answer the
question as to whether people with early stages of the disease might
experience modest benefit from vitamin and/or mineral supple-
mentation.
Visual acuity fluctuates over time and clinical signs of AMD
change, sometimes for the better. The analysis of AREDS took this
variability into account using repeated measures logistic regres-
sion. The advantage of this technique is that it takes into account
all the experiences of the participants over time. The disadvantage
is that some of the transient events countedmay be due to errors in
grading retinal photographs which may not be the most relevant
outcome for the patient. From the patients’ point of view, themost
relevant outcome is the risk of developing permanent visual loss
and established advanced AMD. However, defining ’permanent’
can be problematic. On request, AREDS supplied unpublished
data on AMD and visual acuity outcomes for the five year follow-
up in a format more suitable for incorporation into this review.
However, this did not include information on confirmed cases
prior to the five year follow-up. As this provides less information
than the measures presented in the published report of the study,
I decided not to include these data in the review.
Another difficulty with logistic regression is that the effect mea-
sures are all presented as odds ratios. These have convenient math-
ematical properties but are not always easily interpreted. Most
people tend to think in terms of the relative risk or risk ratio. The
odds ratio approximates the risk ratio when the event rate is low
(less than 10 per cent), but at higher event rates such as seen in this
study the odds ratio exaggerates the benefits (or harms) of treat-
ment. It is possible to calculate risk ratios directly from the report
and the authors report that the risk reduction in progression to
AMD for people with moderate or severe disease is 25% (compare
with odds ratio of 0.66 and therefore odds reduction of 34%).
As AREDS is a large well-conducted randomised study, potential
biases will have been minimised. The only area where bias may
have been introduced is if there were different systemic effects
of the antioxidant and zinc supplementation (e.g., yellowing of
skin or difficulty swallowing tablets) which lead the participants to
guess which group they were in or alternatively, the retinal fundus
photographs might have been different in some way such that the
graders response was affected by treatment group. There is little
evidence that this was a problem in the study.
The other trials included in this review add little to the discussion
of this topic. Theywere too small on their own toprovide definitive
answers and the variety of ways in which outcomes were measured
and reported means that meta-analysis, or pooling of their results,
is impossible.
The three trials of daily supplementation with 200 mg zinc sulfate
were small (less than 200 participants). The results of these trials
were inconsistent - one found a beneficial effect whilst the others
did not. This may reflect differences in the populations studied:
the positive result was looking at progression from early stages of
the disease, whilst the other took people with established neovas-
cular disease and followed-up the second eye. It is difficult to rule
out competing explanations for the effects observed. The study
with negative findings may not have had enough power to detect
a difference; the study with positive findings may have had imbal-
ances in the two groups studied. There is one unpublished trial on
zinc supplementation that is not yet included in this review (170
participants).
The AMDSG trial of broad-spectrum antioxidant supplementa-
tion was too small (59 participants) to detect important effects and
its results must be described as equivocal. The authors reported a
positive finding but the size of the effect was small and was limited
to distance visual acuity in the left eye only. As many parameters
were analysed for right and left eyes, this may be a chance find-
ing. No effect was seen on other measures of visual function or
progression of the disease, with the exception of subjective per-
ception of vision. Similarly the Kaiser 1995 trial of Visaline was
too small to detect differences in visual function (20 participants)
but participants in the control group were more likely to report
worsening of visual function.
None of the trials identified have published data on quality of life
as yet. These data were collected in AREDS and will be published
shortly.
AREDS was the only study to examine effectively the question of
safety. They found little evidence of harm, although in a post-hoc
analysis non-smokers taking antioxidants had a non-significant
increased risk of death. Smokers are at increased risk of developing
advanced AMD, however, the current consensus is that smokers
who take beta-carotenemay be at increased risk of developing lung
cancer (ATBC; Omenn 1996).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
People with moderate to severe age-related macular degeneration
may experience modest delay in progression of the disease with
antioxidant vitamin and mineral supplementation. This finding
is drawn from one large trial conducted in a relatively well-nour-
ished American population. Until it is replicated by other large-
scale trials in other populations we will not know whether these
findings can be applied more generally. There is no evidence that
people with early signs of the disease would benefit from antiox-
idant supplementation. Current studies have been underpowered
to address that question.
Antioxidant vitamin andmineral supplements are readily available
for purchase without prescription inmany countries. The decision
as to whether to take these supplements is at the discretion of
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the person with age-related macular degeneration. The following
benefits and harms need to be considered. People with moderate
or severe disease may delay the progression of their condition if
they take antioxidant vitamins and zinc at the levels described in
this review. Given that there are few other interventions that offer
much in the way of disease prevention or cure this is an important
consideration. However, harmful effects associated with long-term
vitamin supplementation, particularly in smokers, cannot be ruled
out. A healthy diet with a variety of fresh fruit and vegetables will
have many benefits and is unlikely to be harmful. However, it may
be difficult to consume safely as part of a normal diet the levels
of antioxidants and zinc described in the trials included in this
review. For example, one orange provides 80 mg of vitamin C; this
is a relatively high amount. However, one would need to eat six to
seven oranges daily to obtain 500 mg vitamin C.
Implications for research
Trials in other populations, preferably with a variety of nutritional
statuses, are required. These trials should have a large enough
sample size to demonstrate effects that are meaningful for patients
and should also include a component on quality of life.
It is likely that age-related macular degeneration develops over
many years. Three categories of people may be identified: healthy
people at risk because of age or genetic factors; people with early
stages of the disease; people with intermediate or late stage disease.
There are likely to be differences in the potential protective effect
of antioxidant supplementation depending on the stage of the
disease.
N O T E S
The Cochrane Eyes and Vision Group editorial team is aware that
there has been some criticism of one trial included in this review
(AREDS). We welcome comments and criticisms on the review
through the feedback system of the Cochrane Library.
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T A B L E S
Characteristics of included studies
Study AMDSG
Methods Method of allocation: sponsor prepared coded tablets.
Masking:
Participant: not clear,
Provider: yes,
Outcome: yes.
Losses to follow-up: 4 died (2 treatment, 2 control), 1 adverse effect withdrawn (treatment), 7 lost to follow-
up (1 treatment, 6 control).
Participants Country: USA.
Number of participants randomised: 71 veterans.
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Characteristics of included studies (Continued )
Age: average age 72 years.
Sex: 66 male 5 female.
Inclusion criteria: people with a monocular one line drop in Snellen visual acuity not attributable to cataract,
amblyopia, systemic or ophthalmic disease AND clinically observable drusen, RPE disruption and loss of
macular reflex.
Exclusion criteria: greater than one year use of vitamins; ex-prisoners of war, chronic alcoholics with to-
bacco/nutritional amblyopia or gastrointestinal absorption disorders.
Interventions Treatment: Ocuguard (Twin Lab Inc, Ronkonkoma, NY) broad spectrum antioxidant: beta carotene 20,000
IU, vitamin E 200 IU, vitamin C 750 mg, citrus bioflavonoid complex 125 mg, quercitin (bioflavonoid) 50
mg, bilberry extract (bioflavonoid) 5 mg, rutin (bioflavonoid) 50 mg, zinc picolinate 12.5 mg, selenium 50
mcg, taurine 100 mg, n-acetyl cysteine 100mg, l-glutathione 5 mg, vitamin B2 25 mg, chromium 100 mcg.
Control: starch placebo.
Duration: 18 months.
Outcomes Snellen acuity with best refraction converted to LogMAR units for analysis.
Near vision M units with dual sided Bailey-Lovie chart.
Contrast sensitivity.
Retinal grading score (adapted from Chesapeake Bay Study).
Subjective perception of vision.
Adverse gastrointestinal reactions.
Notes Treatment and placebo may not have been identical.
Funders: Twin Laboratories Inc, Ronkokoma NY; Stereo Optical Inc, Chicago, IL.; Eye Communications
Inc, Upland, CA; Illinois College of Optometry, Chicago, IL; Pacific University College of Optometry, Forest
Grove, OR; Ezell Foundation, American Academy of Optometry, Rockville, MD.
Allocation concealment A
Study AREDS
Methods Method of allocation: coded bottles
Masking:
Participant: yes,
Provider: yes,
Outcome: yes.
Losses to follow-up: 2.4% balanced across study groups
Participants Country: USA.
Number of participants randomised: 3640
Age: average age 69 years (range 55-80).
Sex: 56% female.
Inclusion criteria: 20/32 or better in at least one eye; ocular media clear and therefore able to obtain adequate
stereoscopic fundus photographs; at least one eye free from eye disease that could complicate assessment of
AMD.
Exclusion criteria: illness or disorders that wouldmake long term follow-up or compliance with study protocol
unlikely or difficult.
Interventions Treatment: Antioxidants (500mg vitamin C, 400IU vitamin E, 15mg beta carotene) zinc (80mg of zinc as
zinc oxide and 2mg of copper as cupric oxide)
Control: placebo identical in external appearance and similar in internal appearance and taste
Duration: 7 years
Outcomes Primary outcomes: (1) progression to advanced AMD and (2) 15 letter or more decrease in visual acuity score.
AMD assessed using stereoscopic fundus colour photograph; visual acuity measured using EDTRS logMAR
chart. Safety outcomes included: reported adverse events; serum levels of haemoglobin; hospitalisations and
mortality.
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Characteristics of included studies (Continued )
Notes 2x2 factorial design. 67% participants took additional supplements to RDA levels (Centrum). In 1996
current smokers offered option of discontinuing supplementation; 2% of participants and 18% of smokers
did so. A further 2.3% reassigned to no beta-carotene group. Intention to treat analysis maintained.
Allocation concealment A
Study Holz 1993
Methods Method of allocation: not known
Masking:
Participant: yes,
Provider: yes,
Outcome: yes.
Losses to follow-up: not known.
Participants Country: UK.
Number of participants randomised: 58.
Age: 55-82, mean 68.
Interventions Treatment: 100mg zinc sulfate twice daily.
Control: placebo.
Duration: 12 to 24 months.
Outcomes Visual acuity.
Contrast sensitivity.
Dark adaptation.
Stereo fundus photographs and fluorescein angiograms.
Notes Data available from abstract only.
Allocation concealment B
Study Kaiser 1995
Methods Method of allocation: sponsor prepared coded tablets.
Masking:
Participant: yes,
Provider: yes,
Outcome: yes.
Losses to follow-up: None.
Participants Country: Switzerland.
Number of participants randomised: 20.
Age: over 50. Average age 72 in treatment group, 74 in control group.
Sex: 7 male, 20 female.
Inclusion criteria: people with nonserous AMD. All participants had regional atrophy of the pigment epithe-
lium.
Corrected visual acuity was between 20/100 and 20/25 with distance correction of less than four dioptres.
Exclusion criteria: People with diabetes mellitus, endocrine problems, cardiac dysrhythmia, cardial infarction
or hypotension, other ocular disorders.
Interventions Treatment: Visaline (Novopharma Cham, Switzerland). Each tablet contains 1.5mg buphenine HCl, 10 mg
beta-carotene, 10 mg tocopherol acetate, and 50 mg ascorbic acid. Participants took 2 tablets in the morning
and at night, daily except for Saturdays and Sundays.
Control: placebo resembling active treatment prepared by sponsor.
Duration: 6 months.
Outcomes Only one eye per person was evaluated. In cases of bilateral AMD, the eye with better visual acuity was
selected.
Distance and near visual acuity.
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Characteristics of included studies (Continued )
Intraocular pressure.
Visual fields.
Lens opacity.
Retinal visual acuity.
Colour vision.
Contrast sensitivity.
Notes
Allocation concealment A
Study Newsome 1988
Methods Method of allocation: computer generated table of random numbers.
Masking:
Participant: yes,
Provider: yes,
Outcome: yes.
Losses to follow-up: 23 (10 treatment, 13 placebo).
Participants Country: USA.
Number of participants randomised: 174.
Age: 42 to 89.
Sex: 61 men 113 women.
Inclusion criteria: macular degeneration: clinically visible drusen with varying degrees of pigmentary change
with visual acuity in one eye of 20/80 or better.
Exclusion criteria: cataract reducing vision more than one line; other known serious eye disease; diabetes
mellitus; other known systematic/metabolic disease or congenital condition which might interfere with
results.
Interventions Treatment: Zinc sulfate 100mg twice daily.
Control: Identical tablets with lactose and fructose.
Duration: 1-2 years.
Outcomes Pinhole corrected visual acuity using ETDRS charts.
Changes in visible pigment, drusen or atrophy from grading of macular photographs.
Adverse effects of zinc including copper deficiency anaemia.
Notes Funders: Research Fund, Department of Veterinary Science, Utah State University, Logan; James L Shupe,
DVM; Mary Katherine Peterson Foundation, Houston.
Allocation concealment A
Study Stur 1996
Methods Method of allocation: sponsor prepared coded bottles.
Masking:
Participant: yes,
Provider: yes,
Outcome: yes.
Losses to follow-up: 6withdrawndue to adverse gastrointestinal effects (4 treatment, 2 control); 14withdrawn
when developed neovascularisation (9 treatment, 5 control); 14 lost to follow-up (6 treatment, 8 control).
Participants Country: Austria.
Number of participants randomised: 112.
Age: 50 plus.
Sex: 48 men, 64 women.
Inclusion criteria: exudative AMD in one eye (defined as angiographic evidence of classic or occult choroidal
neovascularisation or RPE detachment) and early ARM with visual acuity 20/40 or better in other eye (early
ARM: macular drusen with no angiographic evidence of exudative lesion).
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Exclusion criteria: dense senile cataract; any other eye disease which could produce significant and permanent
loss of visual acuity during follow-up; physical status that could prevent follow-up; history of serious systemic
or metabolic disease.
Interventions Treatment: Zinc sulfate 200 mg once daily. Lemon flavoured effervescent tablet made of citric acid containing
saccharine and sorbitol.
Control: as treatment but without zinc sulfate.
Duration: 24 months.
Outcomes Best corrected LogMAR visual acuity measured using Bailey-Lovie chart.
Contrast sensitivity.
Incidence of choroidal neovascularisation.
Progression of disease (Wisconsin Age-related Maculopathy Grading System).
Copper deficiency anaemia.
Notes A priori sample size estimate was 500 patients but trial stopped early because interim analysis showed no
detectable trend.
Funders: Astra, Linz, Austria; Austrian Foundation for the Propagation of Scientific Research.
Allocation concealment A
Study VECAT
Methods Method of allocation: coded bottles.
Masking:
Participant: yes,
Provider: yes,
Outcome: yes.
Losses to follow-up: not known.
Participants Country: Australia.
Number of participants randomised: 1204.
Age: 55-80 mean 66.
Sex: 56% female
Inclusion criteria: lens and retina of at least one eye available for documentation.
Exclusion criteria: previous cataract surgery or advanced cataract in both eyes; steroid or anticoagulation use;
serious disease; regular use or sensitivity to vitamin E.
Interventions Vitamin E 500 IU per day: natural vitamin E in soybean oil medium.
Control: placebo identical in sight, taste and smell.
Duration: 4 years.
Outcomes 2m logMAR visual acuity; clinical examination; colour stereoscopic fundus photographs graded using Inter-
national Grading Scheme
Notes Worse eye used as the study eye.
Methodology published but results available from abstract only.
Allocation concealment A
AMD - Age-related macular degeneration
RPE - Retinal pigment epithelium
Characteristics of excluded studies
Study Reason for exclusion
Vannas 1958 Allocation concealment inadequate.
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Characteristics of excluded studies (Continued )
A D D I T I O N A L T A B L E S
Table 01. Trials
Trial Intervention Number randomised Outcome Duration
Number with
outcome
Newsome 1988 Zinc 174 Loss of acuity 10
letters or more
24 35
Kaiser 1995 Antioxidants 20 Subjective assessment 6 3
AMDSG Antioxidants plus
zinc
71 Acuity and retinal
grading score
18 ?
Stur 1996 Zinc 112 Development of new
vessels
24 ?
AREDS Antioxidants plus
zinc
3640 Progression to
advanced AMD
60* 718
VECAT Vitamin E 102** Worsening of age-
related maculopathy
48 44
*study follow up was
to 7 years but data
on number of events
only reported for five
years.
**1204 randomised
but only 102 people
followed up had age-
related maculopathy
at baseline
Table 02. AREDS: Effect of treatment on risk of progression to advanced AMD
Comparison OR (All groups) 99% CI OR (mod & severe) 99% CI
Antioxidant versus no antioxidant 0.87 0.70 to 1.09 0.83 0.66 to 1.06
Zinc versus no zinc 0.82 0.66 to 1.03 0.79 0.62 to 0.99
Antioxidant versus placebo 0.80 0.59 to 1.09 0.76 0.55 to 1.05
Zinc versus placebo 0.75 0.55 to 1.03 0.71 0.52 to 0.99
Antioxidant plus zinc versus placebo 0.72 0.52 to 0.98 0.66 0.47 to 0.91
Table 03. AREDS: Effect of treatment on risk of loss of visual acuity score of 15 letters
Comparison OR (all groups) 99% CI OR (mod & severe) 99% CI
Antioxidant versus no antioxidant 0.90 0.74 to 1.09 0.86 0.70 to 1.07
Zinc versus no zinc 0.88 0.73 to 1.07 0.84 0.68 to 1.04
Antioxidant versus placebo 0.88 0.67 to 1.15 0.85 0.63 to 1.14
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Table 03. AREDS: Effect of treatment on risk of loss of visual acuity score of 15 letters (Continued )
Comparison OR (all groups) 99% CI OR (mod & severe) 99% CI
Zinc versus placebo 0.87 0.66 to 1.13 0.83 0.62 to 1.11
Antioxidant plus zinc versus placebo 0.79 0.60 to 1.04 0.73 0.54 to 0.99
A N A L Y S E S
Comparison 01. ZINC SULFATE 200mg DAILY VERSUS PLACEBO
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Increased pigment Odds Ratio (Fixed) 95% CI Totals not selected
02 Increased drusen Odds Ratio (Fixed) 95% CI Totals not selected
03 Increased atrophy Odds Ratio (Fixed) 95% CI Totals not selected
04 Development of new CNV Odds Ratio (Fixed) 95% CI Totals not selected
05 Loss of 10 or more letters
(ETDRS chart)
Odds Ratio (Fixed) 95% CI Totals not selected
06 Visual acuity (logMAR) Weighted Mean Difference (Fixed) 95% CI Totals not selected
07 Contrast sensitivity 3
cycles/degree
Weighted Mean Difference (Fixed) 95% CI Totals not selected
08 Contrast sensitivity 18
cycles/degree
Weighted Mean Difference (Fixed) 95% CI Totals not selected
Comparison 02. OCUGUARD (TM) DAILY VERSUS PLACEBO
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Visual acuity (logMAR) right
eyes
Weighted Mean Difference (Fixed) 95% CI Totals not selected
02 Visual acuity (logMAR) left
eyes
Weighted Mean Difference (Fixed) 95% CI Totals not selected
03 Near vision (m print) right eyes Weighted Mean Difference (Fixed) 95% CI Totals not selected
04 Near vision (m print) left eyes Weighted Mean Difference (Fixed) 95% CI Totals not selected
05 Contrast sensitivity 6 cc/degree
right eyes
Weighted Mean Difference (Fixed) 95% CI Totals not selected
06 Contrast sensitivity 6 cc/degree
left eyes
Weighted Mean Difference (Fixed) 95% CI Totals not selected
07 Subjective perception that
vision declined
Odds Ratio (Fixed) 95% CI Totals not selected
08 Retinal photography grading
results right eyes
Weighted Mean Difference (Fixed) 95% CI Totals not selected
09 Retinal photography grading
results left eyes
Weighted Mean Difference (Fixed) 95% CI Totals not selected
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Comparison 03. VISALINE (TM) VERSUS PLACEBO
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Visual acuity Weighted Mean Difference (Fixed) 95% CI Totals not selected
02 Near vision Weighted Mean Difference (Fixed) 95% CI Totals not selected
03 Subjective assessment vision
declined
Odds Ratio (Fixed) 95% CI Totals not selected
I N D E X T E R M S
Medical Subject Headings (MeSH)
Aged; Antioxidants [therapeutic use; ∗therapeutic use]; ∗Antioxidants [therapeutic use; ∗therapeutic use]; ∗Dietary Supplements;
Macular Degeneration [∗prevention & control]; Minerals [therapeutic use; ∗therapeutic use]; ∗Minerals [therapeutic use; ∗therapeutic
use]; Randomized Controlled Trials; Vitamins [therapeutic use; ∗therapeutic use]; ∗Vitamins [therapeutic use; ∗therapeutic use]
MeSH check words
Humans
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G R A P H S A N D O T H E R T A B L E S
Analysis 01.01. Comparison 01 ZINC SULFATE 200mg DAILY VERSUS PLACEBO, Outcome 01 Increased
pigment
Review: Antioxidant vitamin and mineral supplements for age-related macular degeneration
Comparison: 01 ZINC SULFATE 200mg DAILY VERSUS PLACEBO
Outcome: 01 Increased pigment
Study Control Odds Ratio (Fixed) Odds Ratio (Fixed)
n/N n/N 95% CI 95% CI
Newsome 1988 18/80 25/71 0.53 [ 0.26, 1.09 ]
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Analysis 01.02. Comparison 01 ZINC SULFATE 200mg DAILY VERSUS PLACEBO, Outcome 02 Increased
drusen
Review: Antioxidant vitamin and mineral supplements for age-related macular degeneration
Comparison: 01 ZINC SULFATE 200mg DAILY VERSUS PLACEBO
Outcome: 02 Increased drusen
Study Control Odds Ratio (Fixed) Odds Ratio (Fixed)
n/N n/N 95% CI 95% CI
Newsome 1988 3/80 26/71 0.07 [ 0.02, 0.24 ]
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 01.03. Comparison 01 ZINC SULFATE 200mg DAILY VERSUS PLACEBO, Outcome 03 Increased
atrophy
Review: Antioxidant vitamin and mineral supplements for age-related macular degeneration
Comparison: 01 ZINC SULFATE 200mg DAILY VERSUS PLACEBO
Outcome: 03 Increased atrophy
Study Treatment Control Odds Ratio (Fixed) Odds Ratio (Fixed)
n/N n/N 95% CI 95% CI
Newsome 1988 18/80 38/71 0.25 [ 0.12, 0.51 ]
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Analysis 01.04. Comparison 01 ZINC SULFATE 200mg DAILY VERSUS PLACEBO, Outcome 04
Development of new CNV
Review: Antioxidant vitamin and mineral supplements for age-related macular degeneration
Comparison: 01 ZINC SULFATE 200mg DAILY VERSUS PLACEBO
Outcome: 04 Development of new CNV
Study Treatment Control Odds Ratio (Fixed) Odds Ratio (Fixed)
n/N n/N 95% CI 95% CI
Stur 1996 9/56 5/56 1.95 [ 0.61, 6.25 ]
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Analysis 01.05. Comparison 01 ZINC SULFATE 200mg DAILY VERSUS PLACEBO, Outcome 05 Loss of 10
or more letters (ETDRS chart)
Review: Antioxidant vitamin and mineral supplements for age-related macular degeneration
Comparison: 01 ZINC SULFATE 200mg DAILY VERSUS PLACEBO
Outcome: 05 Loss of 10 or more letters (ETDRS chart)
Study Treatment Control Odds Ratio (Fixed) Odds Ratio (Fixed)
n/N n/N 95% CI 95% CI
Newsome 1988 11/80 24/71 0.31 [ 0.14, 0.70 ]
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 01.06. Comparison 01 ZINC SULFATE 200mg DAILY VERSUS PLACEBO, Outcome 06 Visual
acuity (logMAR)
Review: Antioxidant vitamin and mineral supplements for age-related macular degeneration
Comparison: 01 ZINC SULFATE 200mg DAILY VERSUS PLACEBO
Outcome: 06 Visual acuity (logMAR)
Study Treatment Control Weighted Mean Difference (Fixed) Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI 95% CI
Stur 1996 37 0.05 (0.12) 41 0.03 (0.14) 0.02 [ -0.04, 0.08 ]
-10.0 -5.0 0 5.0 10.0
Favours treatment Favours control
Analysis 01.07. Comparison 01 ZINC SULFATE 200mg DAILY VERSUS PLACEBO, Outcome 07 Contrast
sensitivity 3 cycles/degree
Review: Antioxidant vitamin and mineral supplements for age-related macular degeneration
Comparison: 01 ZINC SULFATE 200mg DAILY VERSUS PLACEBO
Outcome: 07 Contrast sensitivity 3 cycles/degree
Study Treatment Control Weighted Mean Difference (Fixed) Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI 95% CI
Stur 1996 37 71.90 (32.20) 41 70.70 (31.90) 1.20 [ -13.05, 15.45 ]
-10.0 -5.0 0 5.0 10.0
Favours treatment Favours control
Analysis 01.08. Comparison 01 ZINC SULFATE 200mg DAILY VERSUS PLACEBO, Outcome 08 Contrast
sensitivity 18 cycles/degree
Review: Antioxidant vitamin and mineral supplements for age-related macular degeneration
Comparison: 01 ZINC SULFATE 200mg DAILY VERSUS PLACEBO
Outcome: 08 Contrast sensitivity 18 cycles/degree
Study Treatment Control Weighted Mean Difference (Fixed) Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI 95% CI
Stur 1996 37 12.80 (11.00) 41 14.60 (14.70) -1.80 [ -7.53, 3.93 ]
-10.0 -5.0 0 5.0 10.0
Favours treatment Favours control
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Analysis 02.01. Comparison 02 OCUGUARD (TM) DAILY VERSUS PLACEBO, Outcome 01 Visual acuity
(logMAR) right eyes
Review: Antioxidant vitamin and mineral supplements for age-related macular degeneration
Comparison: 02 OCUGUARD (TM) DAILY VERSUS PLACEBO
Outcome: 01 Visual acuity (logMAR) right eyes
Study Treatment Control Weighted Mean Difference (Fixed) Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI 95% CI
AMDSG 35 0.33 (0.41) 24 0.29 (0.24) 0.04 [ -0.13, 0.21 ]
-10.0 -5.0 0 5.0 10.0
Analysis 02.02. Comparison 02 OCUGUARD (TM) DAILY VERSUS PLACEBO, Outcome 02 Visual acuity
(logMAR) left eyes
Review: Antioxidant vitamin and mineral supplements for age-related macular degeneration
Comparison: 02 OCUGUARD (TM) DAILY VERSUS PLACEBO
Outcome: 02 Visual acuity (logMAR) left eyes
Study Treatment Control Weighted Mean Difference (Fixed) Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI 95% CI
AMDSG 35 0.19 (0.24) 24 0.40 (0.49) -0.21 [ -0.42, 0.00 ]
-10.0 -5.0 0 5.0 10.0
Analysis 02.03. Comparison 02 OCUGUARD (TM) DAILY VERSUS PLACEBO, Outcome 03 Near vision (m
print) right eyes
Review: Antioxidant vitamin and mineral supplements for age-related macular degeneration
Comparison: 02 OCUGUARD (TM) DAILY VERSUS PLACEBO
Outcome: 03 Near vision (m print) right eyes
Study Treatment Control Weighted Mean Difference (Fixed) Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI 95% CI
AMDSG 35 1.13 (1.36) 24 1.04 (0.69) 0.09 [ -0.44, 0.62 ]
-10.0 -5.0 0 5.0 10.0
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Analysis 02.04. Comparison 02 OCUGUARD (TM) DAILY VERSUS PLACEBO, Outcome 04 Near vision (m
print) left eyes
Review: Antioxidant vitamin and mineral supplements for age-related macular degeneration
Comparison: 02 OCUGUARD (TM) DAILY VERSUS PLACEBO
Outcome: 04 Near vision (m print) left eyes
Study Treatment Control Weighted Mean Difference (Fixed) Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI 95% CI
AMDSG 35 0.86 (0.59) 24 1.90 (3.87) -1.04 [ -2.60, 0.52 ]
-10.0 -5.0 0 5.0 10.0
Analysis 02.05. Comparison 02 OCUGUARD (TM) DAILY VERSUS PLACEBO, Outcome 05 Contrast
sensitivity 6 cc/degree right eyes
Review: Antioxidant vitamin and mineral supplements for age-related macular degeneration
Comparison: 02 OCUGUARD (TM) DAILY VERSUS PLACEBO
Outcome: 05 Contrast sensitivity 6 cc/degree right eyes
Study Treatment Control Weighted Mean Difference (Fixed) Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI 95% CI
AMDSG 35 5.50 (2.37) 24 5.70 (1.96) -0.20 [ -1.31, 0.91 ]
-10.0 -5.0 0 5.0 10.0
Analysis 02.06. Comparison 02 OCUGUARD (TM) DAILY VERSUS PLACEBO, Outcome 06 Contrast
sensitivity 6 cc/degree left eyes
Review: Antioxidant vitamin and mineral supplements for age-related macular degeneration
Comparison: 02 OCUGUARD (TM) DAILY VERSUS PLACEBO
Outcome: 06 Contrast sensitivity 6 cc/degree left eyes
Study Treatment Control Weighted Mean Difference (Fixed) Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI 95% CI
AMDSG 35 6.20 (1.77) 24 5.63 (2.84) 0.57 [ -0.71, 1.85 ]
-10.0 -5.0 0 5.0 10.0
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Analysis 02.07. Comparison 02 OCUGUARD (TM) DAILY VERSUS PLACEBO, Outcome 07 Subjective
perception that vision declined
Review: Antioxidant vitamin and mineral supplements for age-related macular degeneration
Comparison: 02 OCUGUARD (TM) DAILY VERSUS PLACEBO
Outcome: 07 Subjective perception that vision declined
Study Treatment Control Odds Ratio (Fixed) Odds Ratio (Fixed)
n/N n/N 95% CI 95% CI
AMDSG 5/35 9/24 0.28 [ 0.08, 0.98 ]
0.1 0.2 0.5 1 2 5 10
Analysis 02.08. Comparison 02 OCUGUARD (TM) DAILY VERSUS PLACEBO, Outcome 08 Retinal
photography grading results right eyes
Review: Antioxidant vitamin and mineral supplements for age-related macular degeneration
Comparison: 02 OCUGUARD (TM) DAILY VERSUS PLACEBO
Outcome: 08 Retinal photography grading results right eyes
Study Treatment Control Weighted Mean Difference (Fixed) Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI 95% CI
AMDSG 35 3.08 (1.22) 24 3.31 (1.08) -0.23 [ -0.82, 0.36 ]
-10.0 -5.0 0 5.0 10.0
Analysis 02.09. Comparison 02 OCUGUARD (TM) DAILY VERSUS PLACEBO, Outcome 09 Retinal
photography grading results left eyes
Review: Antioxidant vitamin and mineral supplements for age-related macular degeneration
Comparison: 02 OCUGUARD (TM) DAILY VERSUS PLACEBO
Outcome: 09 Retinal photography grading results left eyes
Study Treatment Control Weighted Mean Difference (Fixed) Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI 95% CI
AMDSG 35 3.08 (1.22) 24 3.53 (0.87) -0.45 [ -0.98, 0.08 ]
-10.0 -5.0 0 5.0 10.0
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Analysis 03.01. Comparison 03 VISALINE (TM) VERSUS PLACEBO, Outcome 01 Visual acuity
Review: Antioxidant vitamin and mineral supplements for age-related macular degeneration
Comparison: 03 VISALINE (TM) VERSUS PLACEBO
Outcome: 01 Visual acuity
Study Treatment Control Weighted Mean Difference (Fixed) Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI 95% CI
Kaiser 1995 9 0.67 (0.20) 11 0.60 (0.22) 0.07 [ -0.11, 0.25 ]
-10.0 -5.0 0 5.0 10.0
Analysis 03.02. Comparison 03 VISALINE (TM) VERSUS PLACEBO, Outcome 02 Near vision
Review: Antioxidant vitamin and mineral supplements for age-related macular degeneration
Comparison: 03 VISALINE (TM) VERSUS PLACEBO
Outcome: 02 Near vision
Study Treatment Control Weighted Mean Difference (Fixed) Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI 95% CI
Kaiser 1995 9 0.62 (0.14) 11 0.55 (0.23) 0.07 [ -0.09, 0.23 ]
-10.0 -5.0 0 5.0 10.0
Analysis 03.03. Comparison 03 VISALINE (TM) VERSUS PLACEBO, Outcome 03 Subjective assessment
vision declined
Review: Antioxidant vitamin and mineral supplements for age-related macular degeneration
Comparison: 03 VISALINE (TM) VERSUS PLACEBO
Outcome: 03 Subjective assessment vision declined
Study Treatment Control Odds Ratio (Fixed) Odds Ratio (Fixed)
n/N n/N 95% CI 95% CI
Kaiser 1995 0/8 3/10 0.13 [ 0.01, 2.86 ]
0.1 0.2 0.5 1 2 5 10
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